Target intelligence / Profile preview

Nuclear factor NF-kappa-B p105 subunit (NFKB1) (NFKB1)

Target
NFKB1
Molecular classification
Transcription factor
01

Overview

Nuclear factor NF-kappa-B p105 subunit (NFKB1) is a pivotal transcription factor that plays a central role in regulating immune responses, inflammatory processes, cell survival, and proliferation. It is synthesized as a large precursor protein, p105, which undergoes proteasome-mediated processing to generate the active p50 subunit. The p50 subunit forms homodimers or heterodimers (most commonly with RelA/p65) to bind specific DNA sequences and regulate gene expression. Under normal physiological conditions, NFKB1 is sequestered in the cytoplasm in an inactive state by inhibitory IκB proteins. Upon stimulation by cytokines, pathogens, or stress, IκB is phosphorylated and degraded, allowing NFKB1 to translocate to the nucleus. Dysregulation of NFKB1 signaling is strongly implicated in chronic inflammatory diseases, autoimmune disorders, and various cancers, where constitutive activation promotes tumor cell survival, metastasis, and resistance to apoptosis. Consequently, NFKB1 and the broader NF-kappaB pathway represent highly attractive therapeutic targets. Pharmacological modulation is achieved through proteasome inhibitors like bortezomib, which prevent IκB degradation, as well as IKK inhibitors and anti-inflammatory agents. However, because NFKB1 is essential for normal host defense and tissue homeostasis, systemic and complete inhibition poses significant safety challenges, including severe immunosuppression and impaired wound healing.

Other names
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1Nuclear factor NF-kappa-B p50 subunitDNA-binding factor KBF1EBP-1NF-kappa-B1NF-kB1p105p50
02

Mechanism of action

Drugs targeting the NF-kappaB pathway primarily act by inhibiting the proteasomal degradation of IκBα (preventing NF-kappaB activation and nuclear translocation), inhibiting IκB kinase (IKK) phosphorylation, or directly blocking the nuclear translocation and DNA-binding activity of the NF-kappaB complex.

03

Biological functions

Transcription regulationImmune responseInflammationApoptosisCell proliferationCell survivalDifferentiation
04

Disease associations

CancerInflammationAutoimmune diseaseInfectionNeurodegenerative disease
05

Safety considerations

ImmunosuppressionIncreased susceptibility to infectionsImpaired tissue repairPotential pro-tumorigenic effects in specific contextsDose-limiting toxicitiesSystemic toxicity due to broad physiological roles
06

Interacting drugs

9 more in the full profile.

07

Biomarkers

NFKB1 expression levelNFKB1 promoter polymorphism (rs28362491)NFKB1 rs230511 haplotypeIκBα phosphorylation statusNuclear translocation of p50/p65Downstream cytokine levels (IL-6, TNF-alpha)

Beyond the preview

Go deeper on Nuclear factor NF-kappa-B p105 subunit (NFKB1) (NFKB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclear factor NF-kappa-B p105 subunit (NFKB1) (NFKB1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call